These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 16188715)

  • 21. Repetitive transcranial magnetic stimulation (rTMS) in combination with escitalopram in patients with treatment-resistant major depression: a double-blind, randomised, sham-controlled trial.
    Bretlau LG; Lunde M; Lindberg L; Undén M; Dissing S; Bech P
    Pharmacopsychiatry; 2008 Mar; 41(2):41-7. PubMed ID: 18311683
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quetiapine as combination treatment with citalopram in unipolar depression with prominent somatic symptoms: a randomised, double-blind, placebo-controlled pilot study.
    Quante A; Regen F; Schindler F; Volkmer K; Severus E; Urbanek C; Luborzewski A; Roepke S; Anghelescu I
    Psychiatr Danub; 2013 Sep; 25(3):214-20. PubMed ID: 24048387
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Repetitive transcranial magnetic stimulation in combination with citalopram in young patients with first-episode major depressive disorder: a double-blind, randomized, sham-controlled trial.
    Huang ML; Luo BY; Hu JB; Wang SS; Zhou WH; Wei N; Hu SH; Xu Y
    Aust N Z J Psychiatry; 2012 Mar; 46(3):257-64. PubMed ID: 22391283
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cognitive-behavioral treatment of adolescent depression: efficacy of acute group treatment and booster sessions.
    Clarke GN; Rohde P; Lewinsohn PM; Hops H; Seeley JR
    J Am Acad Child Adolesc Psychiatry; 1999 Mar; 38(3):272-9. PubMed ID: 10087688
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cognitive behavioral analysis system of psychotherapy and brief supportive psychotherapy for augmentation of antidepressant nonresponse in chronic depression: the REVAMP Trial.
    Kocsis JH; Gelenberg AJ; Rothbaum BO; Klein DN; Trivedi MH; Manber R; Keller MB; Leon AC; Wisniewski SR; Arnow BA; Markowitz JC; Thase ME;
    Arch Gen Psychiatry; 2009 Nov; 66(11):1178-88. PubMed ID: 19884606
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Different interventions for post-ischaemic stroke depression in different time periods: a single-blind randomized controlled trial with stratification by time after stroke.
    Gao J; Lin M; Zhao J; Bi S; Ni Z; Shang X
    Clin Rehabil; 2017 Jan; 31(1):71-81. PubMed ID: 26817808
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled study.
    Khajavi D; Farokhnia M; Modabbernia A; Ashrafi M; Abbasi SH; Tabrizi M; Akhondzadeh S
    J Clin Psychiatry; 2012 Nov; 73(11):1428-33. PubMed ID: 23146150
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Continuation treatment of chronic depression: a comparison of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination.
    Kocsis JH; Rush AJ; Markowitz JC; Borian FE; Dunner DL; Koran LM; Klein DN; Trivedi MH; Arnow B; Keitner G; Kornstein SG; Keller MB
    Psychopharmacol Bull; 2003; 37(4):73-87. PubMed ID: 15131518
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First episode of major depressive disorder and vascular factors in coronary artery disease patients: Baseline characteristics and response to antidepressant treatment in the CREATE trial.
    Habra ME; Baker B; Frasure-Smith N; Swenson JR; Koszycki D; Butler G; van Zyl LT; Lespérance F
    J Psychosom Res; 2010 Aug; 69(2):133-41. PubMed ID: 20624511
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized trial of combined citalopram and naltrexone for nonabstinent outpatients with co-occurring alcohol dependence and major depression.
    Adamson SJ; Sellman JD; Foulds JA; Frampton CM; Deering D; Dunn A; Berks J; Nixon L; Cape G
    J Clin Psychopharmacol; 2015 Apr; 35(2):143-9. PubMed ID: 25679122
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A pilot study of telephone care management and structured disease self-management groups for chronic depression.
    Ludman EJ; Simon GE; Grothaus LC; Luce C; Markley DK; Schaefer J
    Psychiatr Serv; 2007 Aug; 58(8):1065-72. PubMed ID: 17664517
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment as usual (TAU) for depression: a comparison of psychotherapy, pharmacotherapy, and combined treatment at a large academic medical center.
    Blais MA; Malone JC; Stein MB; Slavin-Mulford J; O'Keefe SM; Renna M; Sinclair SJ
    Psychotherapy (Chic); 2013 Mar; 50(1):110-8. PubMed ID: 23505987
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A double-blind, placebo-controlled treatment trial of citalopram for major depressive disorder in older patients with heart failure: the relevance of the placebo effect and psychological symptoms.
    Fraguas R; da Silva Telles RM; Alves TC; Andrei AM; Rays J; Iosifescu DV; Wajngarten M
    Contemp Clin Trials; 2009 May; 30(3):205-11. PubMed ID: 19470312
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.
    Hellerstein DJ; Stewart JW; McGrath PJ; Deliyannides DA; Batchelder ST; Black SR; Withers A; O'Shea D; Chen Y
    J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression.
    Keller MB; McCullough JP; Klein DN; Arnow B; Dunner DL; Gelenberg AJ; Markowitz JC; Nemeroff CB; Russell JM; Thase ME; Trivedi MH; Zajecka J
    N Engl J Med; 2000 May; 342(20):1462-70. PubMed ID: 10816183
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Citalopram in the treatment of dysthymic disorder.
    Hellerstein DJ; Batchelder S; Miozzo R; Kreditor D; Hyler S; Gangure D; Clark J
    Int Clin Psychopharmacol; 2004 May; 19(3):143-8. PubMed ID: 15107656
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial.
    Schaefer M; Sarkar R; Knop V; Effenberger S; Friebe A; Heinze L; Spengler U; Schlaepfer T; Reimer J; Buggisch P; Ockenga J; Link R; Rentrop M; Weidenbach H; Fromm G; Lieb K; Baumert TF; Heinz A; Discher T; Neumann K; Zeuzem S; Berg T
    Ann Intern Med; 2012 Jul; 157(2):94-103. PubMed ID: 22801672
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Residual symptoms after a treated major depressive disorder: in practice ambulatory observatory carried out of city].
    Mouchabac S; Ferreri M; Cabanac F; Bitton M
    Encephale; 2003; 29(5):438-44. PubMed ID: 14615693
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identifying patients at risk of complete nonresponse in the outpatient treatment of depression.
    Van HL; Dekker J; Peen J; van Aalst G; Schoevers RA
    Psychother Psychosom; 2008; 77(6):358-64. PubMed ID: 18701832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.